Matthew W. Foehr

Matthew W. Foehr, listed as chief executive, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in OmniAb, Inc., Ligand Pharmaceuticals Inc and Viking Therapeutics, Inc. In total, 50 filings cover trades dated from 8 January 2016 to 7 April 2026.

The open-market side counts 14 purchases for €7.6M alongside 1 sale for €25k. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 15 share grants and 18 option exercises. 2026 to date brings no purchases and 1 sale.

The median purchase comes to €482k. Of 14 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

On 7 April 2026 came the latest disclosure, an open-market sale for €25k in OmniAb, Inc. The most recent open-market purchase was published on 28 May 2024, 873 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.